Efficacy of saxagliptin in failed glycemic control of patients with type 2 diabetes mellitus
10.3969/j.issn.1005-1678.2016.04.13
- VernacularTitle:沙格列汀对血糖未达标的2型糖尿病患者的疗效
- Author:
Xingzhen WANG
;
Kun WANG
;
Xiaowei ZHENG
;
Jianping CHU
;
Li LI
- Publication Type:Journal Article
- Keywords:
DPP-IV inhibitor;
saxagliptin;
type 2 diabetes mellitus;
HbA1c;
insulin
- From:
Chinese Journal of Biochemical Pharmaceutics
2016;36(4):52-53,57
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the efficacy of saxagliptin in the treatment of failed glycemic control of patients with type 2 diabetes mellitus on the basis of established treatments.Methods 172 cases of failed glycemic control of patients with type 2 diabetes mellitus from June 2013 to December 2014 in department of endocrinology of the first hospital of Ningbo were selected and received health education of 8 weeks, then received saxagliptin on the basis of established treatments for a consecutive treatment of 12 weeks.The HbA1c, fasting blood glucose ( FBG), 2-hours postprandial blood glucose (2hPBG), body mass index (BMI), insulin dosage and adverse event were observed.Results The FBG,HbA1c and 2hPBG after treatment of 12 weeks were significantly lower than those pre-treatment[(7.1 ±2.0)vs.(8.3 ±1.6)mmol/L,(10.2 ±2.3)vs.(15.2 ±2.9)mmol/L,(7.0 ±1.5) vs.(8.0 ±1.7)%], with significant difference (all P <0.05), while there was no significant difference in BMI between pre-and post-treatment [(24.4 ±3.0)vs.(24.9 ±2.7)kg/m2].The insulin dose after treatment of 12 weeks was significantly lower than that pre-treatment[(22.6 ±7.9)vs. (32.3 ±8.2) U/d], with significant difference (P <0.05).There were two patients dropout because of the intolerable digestive tract symptom. Conclusion The adding of saxagliptin could control FBG,2hPBG and HbA1c effectively and decrease insulin dose, without gaining weight in the treatment of failed glycemic control of patients with type 2 diabetes mellitus on the basis of established treatments.
